JP2022539157A5 - - Google Patents

Info

Publication number
JP2022539157A5
JP2022539157A5 JP2021577431A JP2021577431A JP2022539157A5 JP 2022539157 A5 JP2022539157 A5 JP 2022539157A5 JP 2021577431 A JP2021577431 A JP 2021577431A JP 2021577431 A JP2021577431 A JP 2021577431A JP 2022539157 A5 JP2022539157 A5 JP 2022539157A5
Authority
JP
Japan
Prior art keywords
polypeptide
sequence
cancer
cells
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021577431A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022539157A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2020/051557 external-priority patent/WO2020260897A1/en
Publication of JP2022539157A publication Critical patent/JP2022539157A/ja
Publication of JP2022539157A5 publication Critical patent/JP2022539157A5/ja
Pending legal-status Critical Current

Links

JP2021577431A 2019-06-28 2020-06-26 新規な癌抗原及び方法 Pending JP2022539157A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19183318.5 2019-06-28
EP19183318 2019-06-28
EP20170163.8 2020-04-17
EP20170163 2020-04-17
PCT/GB2020/051557 WO2020260897A1 (en) 2019-06-28 2020-06-26 Novel cancer antigens and methods

Publications (2)

Publication Number Publication Date
JP2022539157A JP2022539157A (ja) 2022-09-07
JP2022539157A5 true JP2022539157A5 (enExample) 2023-07-05

Family

ID=71266763

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021577431A Pending JP2022539157A (ja) 2019-06-28 2020-06-26 新規な癌抗原及び方法

Country Status (11)

Country Link
US (1) US20220220175A1 (enExample)
EP (1) EP3990006A1 (enExample)
JP (1) JP2022539157A (enExample)
KR (1) KR20220029561A (enExample)
CN (1) CN114341169B (enExample)
AU (1) AU2020302285A1 (enExample)
BR (1) BR112021026364A2 (enExample)
CA (1) CA3141553A1 (enExample)
IL (1) IL289200A (enExample)
MX (1) MX2021015765A (enExample)
WO (1) WO2020260897A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021006941A2 (pt) 2018-10-19 2021-08-31 The Francis Crick Institute Limited Antígenos de câncer inovadores e métodos
CA3179694A1 (en) * 2020-04-17 2021-10-21 The Francis Crick Institute Limited Fusion proteins of ctl antigens for treating melanoma
JP2023522193A (ja) * 2020-04-17 2023-05-29 ザ フランシス クリック インスティチュート リミティッド 抗原プール
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
JP2003304877A (ja) * 2002-04-15 2003-10-28 Keio Gijuku ヒト色素細胞特異分子
EP1586330A1 (en) 2004-04-16 2005-10-19 Georg-August-Universität Göttingen Vaccination against malignant melanoma
DK1871391T3 (da) 2005-03-30 2012-04-16 Viroxis Endogen retrovirus og proteiner, der kodes af env som target for cancerbehandling
AT502292B1 (de) 2005-05-11 2010-04-15 Avir Green Hills Biotechnology Melanomdiagnose
US8921050B2 (en) 2006-03-17 2014-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of diagnosing renal cell carcinoma
US20080019979A1 (en) 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods
WO2009039244A2 (en) * 2007-09-18 2009-03-26 Genizon Biosciences Inc. Genemap of the human genes associated with crohn's disease
SG11201808629UA (en) * 2016-04-21 2018-11-29 Immatics Biotechnologies Gmbh Immunotherapy against melanoma and other cancers
JP7642530B2 (ja) * 2018-09-04 2025-03-10 トレオス バイオ リミテッド ペプチドワクチン
BR112021006941A2 (pt) * 2018-10-19 2021-08-31 The Francis Crick Institute Limited Antígenos de câncer inovadores e métodos

Similar Documents

Publication Publication Date Title
JP5239041B2 (ja) 癌の治療剤
US9463228B2 (en) Application of mRNA for use as a therapeutic against tumour diseases
RU2526510C2 (ru) Композиция для лечения рака легких, прежде всего, немелкоклеточного рака легких (нмкрл)
JP2022539157A5 (enExample)
JP5709264B2 (ja) ワクチン組成物および方法
EP1658097A1 (en) Nucleotide and cellular vaccine composition
JP2007523863A (ja) 予防又は治療目的のためのｍｈｃクラスｉ拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法
JP2022538609A5 (enExample)
AU2015233542A1 (en) A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
JP2015520129A (ja) 多価乳がんワクチン
CN101146550A (zh) 用于预防或治疗目的的激发、增强和维持对i类mhc-限制性表位的免疫应答的方法
US20170281752A1 (en) Antigen Delivery System
JP2022514116A5 (enExample)
JP2022539585A5 (enExample)
KR101810840B1 (ko) 암의 예방 및 치료용 msi-특이적 프레임쉬프트 펩티드(fsp)
JP2022540396A5 (enExample)
CA2466530A1 (en) Allogenic vaccine that contains a costimulatory polypeptide-expressing tumor cell
CN119770632A (zh) 诱导免疫应答的组合物和方法
JP2011506497A5 (enExample)
CN112011833A (zh) 筛选和分离肿瘤新生抗原的方法
WO2015005479A1 (ja) 腫瘍抗原ペプチド
Hersey et al. Melanoma vaccines
US20260021184A1 (en) Cancer Antigens and Methods
WO2025224446A1 (en) Novel cancer antigens and methods
CLONES Genes Coding for Antigens Recognized on Human Tumors by Autologous Cytolytic T Lymphocytes zyxwvutsrqpon